TRETTEN Drug Profile

Summary for Tradename: TRETTEN

High Confidence Patents:	8
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for TRETTEN

Recent Clinical Trials for TRETTEN

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Novo Nordisk A/S

See all TRETTEN clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for TRETTEN Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for TRETTEN Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Novo Nordisk Inc.	TRETTEN	coagulation factor xiii a-subunit (recombinant)	For Injection	125398	10,316,091	2038-06-29	DrugPatentWatch analysis and company disclosures
Novo Nordisk Inc.	TRETTEN	coagulation factor xiii a-subunit (recombinant)	For Injection	125398	10,391,062	2029-04-20	DrugPatentWatch analysis and company disclosures
Novo Nordisk Inc.	TRETTEN	coagulation factor xiii a-subunit (recombinant)	For Injection	125398	10,550,186	2035-12-02	DrugPatentWatch analysis and company disclosures
Novo Nordisk Inc.	TRETTEN	coagulation factor xiii a-subunit (recombinant)	For Injection	125398	11,084,880	2038-11-21	DrugPatentWatch analysis and company disclosures
Novo Nordisk Inc.	TRETTEN	coagulation factor xiii a-subunit (recombinant)	For Injection	125398	11,396,556	2040-01-22	DrugPatentWatch analysis and company disclosures
Novo Nordisk Inc.	TRETTEN	coagulation factor xiii a-subunit (recombinant)	For Injection	125398	8,937,166	2033-06-27	DrugPatentWatch analysis and company disclosures
Novo Nordisk Inc.	TRETTEN	coagulation factor xiii a-subunit (recombinant)	For Injection	125398	9,309,315	2026-08-18	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for TRETTEN Derived from Patent Text Search

No patents found based on company disclosures

International Patents for TRETTEN

Country	Patent Number	Estimated Expiration
Australia	2024203938
Israel	318221
Australia	2016228196
South Korea	20150020189
Japan	2018095649
Israel	250043
Taiwan	I750110

Market Dynamics and Financial Trajectory for TRETTEN

Last updated: April 11, 2026

What is TRETTEN?

TRETTEN (liraglutide injection) is a GLP-1 receptor agonist approved by the FDA for weight management in adults with obesity or overweight with comorbidities. Developed by Novo Nordisk, it entered the market in August 2023.

Market Overview

The global obesity pharmacotherapy market is projected to reach $20 billion by 2028, growing at a CAGR of 13%. The increasing prevalence of obesity and rising awareness of medical options drive this growth.

Key Competitors

Drug	Manufacturer	Indications	Market Launch Year
TRETTEN (liraglutide)	Novo Nordisk	Weight management, type 2 diabetes	2023
Wegovy (semaglutide)	Novo Nordisk	Obesity	2021
Saxenda (liraglutide)	Novo Nordisk	Obesity, weight management	2014
Orlistat (Alli, Xenical)	Roche, GSK	Weight management	1999

Market Dynamics

Drivers

• Rising Obesity Rates: Worldwide obesity prevalence has doubled in past decades; over 650 million adults classified as obese (WHO, 2022).
• FDA Approvals for Weight Loss: The 2023 approval of TRETTEN positions it as a competitive alternative.
• Patient Preference for Injectable Therapies: Growing acceptability for injectable drugs with proven efficacy.
• Insurance Coverage Expansion: Coverage for obesity treatments increases patient access.

Challenges

• Pricing and Reimbursement: High cost limits accessibility; reimbursement policies differ globally.
• Competition: Limited but growing presence of oral GLP-1 options and combination therapies.
• Adherence: Injection frequency (once daily) impacts compliance.

Regulations and Approvals

• FDA approval in August 2023.
• Pending regulatory reviews in Europe (EMA) and Asia-Pacific.
• Ongoing post-marketing studies on safety and efficacy.

Financial Trajectory

Revenue Projections

Year	Estimated Revenue	Key Factors
2023	$0.5 billion	Launch year, initial adoption
2024	$1.2 billion	Growing prescription volume
2025	$2.5 billion	Expanded access, insurance reimbursement
2026	$4.2 billion	Increased competition, market penetration

Factors Influencing Revenue

• Market Penetration: Early adoption among high-risk, weight-focused patients.
• Pricing Strategy: Premium pricing (~$1,200/month in the U.S.) influences margins.
• Market Expansion: Regulatory approval in new regions essential for growth.
• Dosing and Administration Costs: Injection form contributes to higher treatment costs.

Investment & R&D

• Novo Nordisk invests heavily in obesity and diabetes treatments, with 2022 R&D expenditures exceeding $2 billion.
• Focus on delivery innovations and combination therapies to extend market share.

Risks And Opportunities

• Patent Expiry: No imminent patent loss for liraglutide, extending exclusivity.
• Pipeline Potential: New formulations and indications could expand market scope.
• Competitive Innovations: Oral GLP-1 formulations could disrupt injectable markets.

Market Entry Barriers

• High development costs (~$1 billion per compound).
• Strict regulatory approval processes for new indications.
• Market saturation risk from existing therapies.

Summary

TRETTEN's market entry in 2023 positions it as a key player in obesity pharmacotherapy. Market growth depends on acceptance, reimbursement landscape, and competition from oral agents and combination therapies. Financial growth is expected to be robust in the next five years, driven by increasing obesity prevalence, expanded approvals, and ongoing marketing efforts.

Key Takeaways

• TRETTEN faces a growing obesity drug market with significant unmet needs.
• Novo Nordisk’s established position supports rapid uptake.
• Reimbursement policies and pricing strategies are critical to revenue performance.
• Competition from oral GLP-1s and multi-modal therapies introduces future risks.
• Long-term success depends on pipeline development and regulatory expansions.

FAQs

1. How does TRETTEN differ from Wegovy?

   TRETTEN (liraglutide) is approved for weight management; Wegovy (semaglutide) has demonstrated higher efficacy in weight loss. Both are injectable GLP-1 receptor agonists, but Wegovy's higher potency offers potentially greater weight reduction.

2. What are the main barriers to market growth?

   Cost and reimbursement limitations, patient adherence to injectable regimens, and competition from oral medications.

3. How likely is FDA approval for similar drugs?

   The FDA approves similar GLP-1 receptor agonists based on efficacy and safety data; ongoing studies suggest high approval probability for new formulations.

4. What regions represent significant growth opportunities?

   Europe, Asia-Pacific, and Latin America are emerging markets due to rising obesity prevalence and expanding healthcare access.

5. Will TRETTEN's market share expand significantly?

   Yes, with continued marketing, coverage expansion, and pipeline innovations, TRETTEN can secure a significant portion of the obesity pharmacotherapy market.

References

[1] World Health Organization. (2022). Obesity and Overweight. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight

[2] Novo Nordisk. (2023). TRETTEN (liraglutide) Prescribing Information. https://www.novo-pi.com/tretten.pdf

[3] MarketWatch. (2023). Obesity Pharmacotherapy Market Size, Trends & Forecast. https://www.marketwatch.com/obesity-pharmacotherapy-market

[4] FDA. (2023). FDA Approves TRETTEN for Weight Management. https://www.fda.gov/news-events/press-announcements

[5] IQVIA Institute. (2022). The Global Use of Medicines in 2022. https://www.iqvia.com/research/insights/the-global-use-of-medicines-2022